ArticleCureus2025
Estimation of the Serum Levels of Brain-Derived Neurotrophic Factor (BDNF) and Interleukin-1β and Their Correlation With Clinical Severity in Depression Patients: A Case-Control Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neurotrophins and Galectin-3: Hidden Keys in Neuroinflammation-A Narrative Review.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDepression is a complex psychiatric disorder with no universally accepted risk assessment tools. The pathogenesis of depression remains incompletely understood, and the exact mechanisms underlying its onset are still debated. A prevailing hypothesis suggests that dysregulated cytokine production, driven by immune system hyperactivation, may play a role in the development of depression.
methodsThis study aimed to investigate alterations in serum levels of brain-derived neurotrophic factor (BDNF) and Interleukin-1β (IL-1β) in individuals with depression and assess their potential roles as biomarkers. This was a case-control study. Cases diagnosed with depression were compared with healthy controls. The severity of depression was assessed using the Hamilton Depression Rating Scale (HDRS). Serum levels of BDNF and IL-1β were quantified using enzyme-linked immunosorbent assay (ELISA) kits procured from MyBioSource company.
resultsPatients with depression exhibited significantly higher serum levels of IL-1β and lower levels of BDNF compared to healthy controls. Moreover, a significant positive correlation was found between IL-1β levels and HDRS scores, while BDNF levels showed a significant negative correlation with HDRS scores.
conclusionOur findings suggest that serum IL-1β levels are positively correlated, while BDNF levels are negatively correlated, with the severity of depression. These biochemical markers may serve as potential risk assessment indicators and biomarkers for depression, providing insight into the underlying mechanisms of the disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.